CTLA4 and cancer: Immunotherapy, particularly immune checkpoint blockade (ICB) targeting pathways such as PD-1/PD-L1 and CTLA-4, has emerged as a highly promising therapeutic approach for multiple cancers, including HCC (Rimassa, Finn & Sangro, 2023; Xing et al., 2021).